Effects of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression: a multi-state survival model.

ABSTRACT:

Background

Current guidelines recommend good glycemic control in patients with type 2 diabetes (T2D) to limit the progression of associated complications with combination therapies. This study aimed to compare the rate of chronic kidney disease (CKD) progression between patients who did or did not receive sodium-glucose cotransporter-2 inhibitors (SGLT2i) using a multistate model with two intermediate states (i.e., CKD stage 4 (CKD4) and 5 (CKD5)) and one absorbing state (i.e., death).

Methods

Data from patients with T2D and CKD stage 3 (CKD3) were retrieved for analysis. Patients treated with SGLT2i were matched 1:2 by prescription date with non-SGLT2i patients. The multistate model was constructed from Cox survival regression models specific to each transition stage. Cumul

SUBMITTER: Tansawet A 

PROVIDER: S-EPMC11585174 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature